A 72-year-old male has a history of stage II renal clear cell carcinoma, atrial fi brillation, and a radial nephrectomy. The patient remained disease free until 9 years after nephrectomy when he manifested metastatic disease. He had been receiving amiodarone for atrial fi brillation for 1 year before his metastatic cancer diagnosis, but it was stopped preemptively to prevent drug interactions before the initiation of tyrosine kinase inhibitor (TKI) treatment. The patient received pazopanib (Votrient) for 6 months when, based on disease progression, he started receiving sorafenib (Nexavar) 400 mg twice daily. The patient deteriorated after 2 to 3 weeks of therapy and progressed over 5 weeks with anorexia, diaphoresis, fatigue, tremors, diarrhea, and intermittent confusion.
thyroid gland and a fi ne resting tremor. He had markedly abnormal thyroid function tests (TFTs) with an undetectable thyroid stimulating hormone (TSH) of less than 0.008 μIU/mL, elevated free T4 (fT4) of 4.06 ng/dL (reference range, 0.89 to 1.76 ng/dL), T4 of 19 μg/dL (reference range, 4.5 to 10.9 μg/dL), and mildly elevated free T3 (fT3) of 4.4 pg/ mL (reference range, 2.3 to 4.2 pg/mL). Thyroglobulin was elevated at 115 ng/mL (reference range, 1.6 to 59.9 ng/mL), whereas antithyroglobulin, antithyroid peroxidase, and thyroid-stimulating immunoglobulin were undetectable. The patient had a thyroid ultrasound that revealed a heterogenous and atrophic right thyroid lobe with no focal lesions. He was diagnosed with thyroid storm and treated with high-dose propylthiouracil, hydrocortisone, and propranolol. The patient's confusion persisted and his atrial fi brillation remained poorly controlled with intravenous diltiazem and a beta blocker. Three days after admission, the patient had a cardiac arrest in the setting of aspiration and died.
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The authors discussed that the 4 TKIs on the market -sunitinib (Sutent), sorafenib (Nexavar), pazopanib (Votrient), and axitinib (Inlyta) -are associated with TKI-induced thyroid dysfunction. Hypothyroidism is generally associated with sunitinib, with 30% of patients requiring thyroid hormone replacement therapy. The lowest reported incidence of patients developing hypothyroidism is associated by pazopanib, and there are currently no data available on TSH trends in patients receiving pazopanib.
The patient had normal baseline TFTs and presented with thyroid storm 8 weeks after initiating sorafenib. He had no signifi cant drug-drug interactions between sorafenib and other medications, and he had not received iodine-containing contrast after initiating sorafenib. The authors theorize that several mechanisms may explain TKI-induced thyroid dysfunction. One mechanism could be VEGF inhibition that causes capillary regression to several organs with the greatest regression to the thyroid gland, which suggests that the thyroid gland may be particularly sensitive to inhibition. A second mechanism is the possible blocking of iodine uptake by TKIs. Clinically, TKI-induced thyroid dysfunction does not seem to be mediated by autoimmune mechanisms, given that antithyroid peroxidase activity and antithyroglobulin antibodies have been found to be negative in most patients with thyroid dysfunction. The authors propose that more than one mechanism causes TKIinduced thyroid dysfunction, given that some patients develop thyroiditis with or without symptoms of hyperthyroidism, whereas others do not. It is also likely that the incidence of thyrotoxicosis is underestimated, because the symptoms are nonspecifi c and overlap with other TKI-induced adverse effects.
The authors state that optimal therapy for TKIinduced thyrotoxicosis is unknown. If thyroiditis is the cause for most cases of TKI-induced thyrotoxicosis, initiating antithyroid medication is unlikely to be helpful. Although one previous case report demonstrated benefi t with glucocorticoids, the current patient did not benefi t from glucocorticoids. Guidelines for thyroid function monitoring have not been developed, but several authors have suggested monitoring TSH for the fi rst 4 months of therapy, given that thyroid dysfunction tends to occur early. Patients with preexisting thyroid dysfunction may require closer monitoring, and patients who discontinue therapy may also require monitoring given that thyroid dysfunction can resolve once therapy is stopped.
The authors surmise that sorafenib-induced thyroid storm may be under-recognized, because the symptoms of thyroid storm can overlap with symptoms of other TKI-related toxicities. Monitoring is essential; thyroid storm requires prompt recognition and treatment because of the high mortality associated with this condition. 
CEFTAROLINE-INDUCED EOSINOPHILIC PNEUMONIA
A 46-year-old male who was morbidly obese (body mass index [BMI] = 56) with type II diabetes mellitus underwent a spinal surgery and developed a surgical site infection and bacteremia secondary to methicillin-resistant Staphylococcus aureus (MRSA). The vancomycin MIC for the MRSA isolate was 2 mcg/mL; based on this information and the patient's body weight (173 kg), ceftaroline (Tefl aro) was initiated. Pathogen susceptibility to ceftaroline was confi rmed (MIC of 0.75 mcg/mL) and the patient was discharged to an extended care facility with ceftaroline 600 mg intravenously every 8 hours for a planned 6 weeks of therapy.
The patient developed shortness of breath, dry cough, and hypoxemia on day 39 of ceftaroline therapy. He was hospitalized and was noted not to have fever or chills. Vital signs on admission were temperature of 97.5°F, heart rate 105 bpm, respiratory rate 32 beats/min, blood pressure 125/66 mm Hg, and an oxygen saturation of 90% while receiving 5 L of oxygen via nasal cannula. Contributory lab data included an elevated white blood count of 12,000/mm 3 (reference range, 4.1-10.9/mm 3 ) with an absolute eosinophil count of 1,500/mm 3 (reference value, < 350/mm 3 ). Chest x-ray showed bilateral patchy nodular infi ltrates, and a CT scan of the chest revealed diffuse bilateral infi ltrates with bilateral hilar and mediastinal adenopathy. The patient's history included no history of asthma, and he was a lifelong nonsmoker. He had not started any new medications, and there was no travel history suggestive of environmental exposure since the patient had been discharged to an extended care facility to receive his intravenous ceftaroline therapy.
Upon admission, the patient's ceftaroline was discontinued and aztreonam and tigecycline were initiated as presumptive therapy for suspected pneumonia caused by ceftaroline-resistant pathogens. The patient's respiratory status worsened over the next 48 hours, and he required noninvasive ventilation. A broncho-alveolar lavage (BAL) was performed and demonstrated 16% eosinophils, 62% neutro-phils, and 20% lymphocytes. Eosinophilic lung disease can be identifi ed by the presence of an increased number of eosinophils in the lung or BAL fl uid in a patient with pulmonary symptoms or infi ltrates on chest x-ray. Based on the fi ndings, ceftarolineinduced eosinophilic pneumonia was suspected, and the patient was initiated on intravenous methylprednisolone. He experienced signifi cant improvement over the next 24 hours. The patient was then weaned off of oxygen; after an 8-day hospital stay, he was discharged with a prednisone taper as well as an extended course of doxycycline as a follow-up therapy for his MRSA spine infection.
The authors review the possible mechanism of drug-induced eosinophilic pneumonia. The mechanism is not well understood, but interleukin-5, which is produced by T-helper cells, is the main cytokine promoting eosinophil production. The abundance of macrophages in the lung could result in large local production of interleukin-5 with the consequence of preferential accumulation of eosinophils. Because ceftaroline has signifi cant penetration into the lungs, the prolonged use of high-dose ceftaroline may result in persistent and possibly increased exposure to lung tissue macrophages. It is important to note that the patient in this case received ceftaroline 600 mg every 8 hours; ceftaroline has been reported to cause peripheral eosinophilia when administered for an extended duration (up to several weeks). Ceftaroline was administered in clinical trials at a dose of 600 mg every 12 hours for up to 14 days.
The authors caution that health care providers should be alert for patients who develop respiratory symptoms in combination with new pulmonary infi ltrates with or without peripheral eosinophilia in patients treated with ceftaroline. Ceftaroline-induced eosinophilic pneumonia should then be suspected. 
IMATINIB-INDUCED OSTEONECROSIS OF THE TIBIA
A 61-year-old female was diagnosed with metastatic gastrointestinal stromal tumor (GIST) and was initiated on imatinib (Gleevec) four 100 mg capsules daily. After 3 months of treatment, partial response was documented as assessed by CT scan. At 6 months, however, the patient complained of bone pain in both lower extremities, with limping gait and limited range of motion. A whole-body bone scan and an MRI were completed, and they revealed osteonecrosis of the tibia.
A pharmacokinetic assessment of the patient indicated that the blood level of imatinib was 2,020 ng/mL. The patient had no evidence of an underlying metabolic bone disorder. Imatinib was discontinued and replaced with nilotinib (Tasigna). The patient's bone pain subsided immediately, and she recovered her range of motion. Follow-up bone scans completed 2 and 6 months after the discontinuation of imatinib indicated a reduction in the severity of osteonecrosis.
A subsequent CT scan performed 6 months after the start of nilotinib demonstrated GIST disease progression. Imatinib 400 mg daily was restarted; after 1 month of treatment, the blood level of imatinib was 4,040 ng/mL. A subsequent CT scan revealed a partial response after the patient had taken imatinib for 3 months; however, the patient experienced bone pain in both lower extremities. A bone scan revealed increased osteonecrosis of the tibia.
The authors point out that imatinib is considered the standard fi rst-line agent for the treatment of unresectable or metastatic GIST. Common adverse effects (diarrhea, edema, asthenia, myalgia, and skin reactions) are most often mild and manageable. Musculoskeletal complaints are a common adverse effect of imatinib therapy, affecting approximately 40% of patients. Musculoskeletal adverse effects are typically mild to moderate in severity and manifest as muscle cramps and/or pain, primarily occurring in the hands, feet, calves, and thighs with a varying pattern, frequency, and severity. Bone pain and arthralgia have been reported in up to 14% of patients with GIST who are receiving 400 mg of imatinib daily. The associated symptoms (which can be severe, disabling, and strikingly asymmetric) primarily affect the femur, tibia, hip, and knee. Imatinib administration may be associated with hypophosphatemia and hyperphosphaturia and with changes in bone and mineral metabolism, which is possibly mediated by inhibition of osteoclast function.
The authors summarize that the temporal relationship suggests that the patient's osteonecrosis was induced by imatinib; osteonecrosis of the tibia with decreased perfusion occurred a few months after imatinib therapy was initiated. The condition improved after the drug was discontinued and rapidly worsened after treatment was resumed. Although extensive clinical experience supports the safe use of imatinib, the current case report suggests that imatinib may cause osteonecrosis of the tibia in a small proportion of patients.
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